Sinco Pharmaceuticals Holdings Limited (6833)

Overview

Sinco Pharmaceuticals Holdings Limited operates as an investment holding company primarily in China, where it provides comprehensive marketing, promotion, and channel management services for a range of imported pharmaceutical products and medical devices. Founded in 2011 and headquartered in Chengdu, People's Republic of China, Sinco Pharmaceuticals has expanded its reach and impact in the pharmaceutical industry. It is a key subsidiary of Risun Investments Limited, reflecting its strategic importance and integrated role within the larger corporate structure. Beyond its core activities, the company engages in diverse operations including research and development, sales of pharmaceuticals, provision of warehouse facilities for pharmaceutical products, involvement in international trade, consultation services for medical and biological technology, and offering medical beauty services. This broad range of services underscores Sinco Pharmaceuticals’ commitment to contributing significantly to healthcare and medical services, leveraging innovation, and providing solutions that meet the growing demands of its market.

Products and Services

Sinco Pharmaceuticals Holdings Limited offers a comprehensive portfolio of pharmaceutical products and medical services, tailored to meet the diverse needs of its customer base:

• Octapharma: A vital human albumin solution designed specifically for premature infants, showcasing the company’s commitment to addressing critical neonatal health challenges.
• Axetine: This versatile antibiotic is employed in treating bacterial infections, including respiratory, urinary tract, and soft tissue infections, among others. It also plays a crucial role in the prevention of infections post-surgery, illustrating the breadth of Sinco’s antibiotic range.
• Medocef: Focused on combating bacterial infections, Medocef is effective against several types of infections such as those affecting the lower respiratory tract, urinary tract, and more, reinforcing the company's strong presence in anti-infective treatments.
• Esafosfina: Addressing conditions like hypophosphatemia along with chronic diseases such as alcohol intoxication and malnutrition, Esafosfina showcases Sinco’s dedication to treating a broad spectrum of ailments.
• Taurolite: Specializing in the treatment of gallstone diseases, this third-generation oral cholic acid drug highlights the company’s efforts in addressing gastroenterological conditions.
• Tamifil injection: Used in the treatment of metastatic prostate cancer, true precocious puberty, and endometriosis, Tamifil injection represents Sinco's foray into specialized therapeutic areas including oncology and endocrinology.

In addition to these pharmaceutical products, Sinco Pharmaceuticals is involved in research and development, which aids in the innovation and enhancement of its product offerings. The company’s services extend to providing warehousing for pharmaceutical products, engaging in international trade, offering consultation services in medical and biological technology, and delivering medical beauty services, thereby providing a holistic approach to healthcare and wellness.